Evidence map›Paper›PMID 42644888›Full record

ReviewEpidemiologia (Basel, Switzerland)2026

Reproducible Gut Microbiome Alterations in Major Depressive Disorder: A Systematic Review of Taxonomic and Functional Findings.

Gulshat Dalibayeva, Maya Goremykina, Samat Kozhakhmetov, Almagul Kushugulova, Alibek Kossumov, Sundetgali Kalmakhanov, Ainur Doszhan

Abstract readReview
In one paragraph

Review in Epidemiologia (Basel, Switzerland), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Gulshat DalibayevaFaculty of Medicine and Health Care, Al-Farabi Kazakh National University, Almaty 050040, Kazakhstan.ORCID 0009-0009-5348-9739
Maya GoremykinaDepartment of Internal Medicine and Rheumatology, Semey Medical University NJSC, Semey 071400, Kazakhstan.ORCID 0000-0002-5433-7771
Samat KozhakhmetovNational Laboratory Astana, Nazarbayev University, Astana 010000, Kazakhstan.ORCID 0000-0001-9668-0327
Almagul KushugulovaNational Laboratory Astana, Nazarbayev University, Astana 010000, Kazakhstan.ORCID 0000-0001-9479-0899
Alibek KossumovNational Laboratory Astana, Nazarbayev University, Astana 010000, Kazakhstan.ORCID 0000-0001-7827-6697
Sundetgali KalmakhanovFaculty of Medicine and Health Care, Al-Farabi Kazakh National University, Almaty 050040, Kazakhstan.
Ainur DoszhanJSC National Scientific Medical Center, Astana 010009, Kazakhstan.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

BACKGROUND/

objectivesMajor depressive disorder (MDD) has been increasingly associated with alterations of the gut microbiome through the microbiota-gut-brain axis. However, published findings remain highly heterogeneous, limiting identification of reproducible microbial signatures associated with depression. This systematic review aimed to evaluate reproducible taxonomic and functional gut microbiome alterations in patients with MDD compared with healthy controls.

methodsA systematic literature search was conducted in PubMed/MEDLINE, Scopus, Web of Science Core Collection, and the Cochrane Library for studies published between January 2016 and December 2025. Observational human studies evaluating gut microbiome composition in adults with clinically diagnosed MDD and healthy control groups were included. Methodological quality was assessed using the Newcastle-Ottawa Scale. Due to substantial methodological heterogeneity, findings were synthesized using structured qualitative narrative analysis.

resultsSixteen observational studies were included in the qualitative synthesis. Findings related to alpha diversity were inconsistent across studies, whereas beta diversity alterations demonstrated greater reproducibility across independent cohorts. The most recurrent microbiome pattern involved depletion of short-chain fatty acid (SCFA)-producing bacteria, particularly Faecalibacterium and Roseburia, together with recurrent alterations affecting members of the Ruminococcaceae, Lachnospiraceae, and Clostridia groups. Functional microbiome alterations demonstrated greater consistency than higher-level taxonomic findings and included reduced butyrate synthesis pathways, dysregulated amino acid and tryptophan metabolism, increased lipopolysaccharide biosynthesis, and enrichment of pro-inflammatory microbial signatures. Antidepressant-naïve cohorts generally demonstrated more homogeneous dysbiosis patterns than mixed-treated populations.

conclusionsCurrent evidence suggests that functional gut microbiome dysregulation may represent a more reproducible biological feature of MDD than isolated taxonomic alterations alone. However, substantial heterogeneity in study design, participant characteristics, sequencing methodologies, and analytical approaches continues to limit clinical translation. Large-scale longitudinal multi-omics studies using standardized methodologies are required to clarify the role of the gut microbiome in depressive disorders and to evaluate the potential utility of microbiome-based biomarkers and interventions in mental health and public health practice.

Indexed as

depressiondysbiosisgut microbiomemajor depressive disordermetagenomicsmicrobiomemicrobiota–gut–brain axis

Identifiers

PMID42644888
PMCPMC13511779

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.